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Perfusion processes have demonstrated significantly higher volumetric productivity while maintaining consistent 
product quality attributes (PQAs) throughout an extended harvest period. With this, a drastic decrease of the 
bioreactor footprint in future commercial plants can be achieved. Therefore, there are significant efforts in 
biopharmaceutical industry focused on developing high productivity perfusion process for both future biologics, 
as well as on developing new generation processes for legacy fed-batch processes. 
 
In this presentation, we will report the adaptation of an established 14-day fed-batch process for a therapeutic 
monoclonal antibody to a 30-day perfusion process using alternating tangential flow (ATF) technology. In the 
proof-of-concept perfusion process, a 6-fold viable cell density (VCD) was reached and maintained compared to 
the peak VCD in the fed-batch process. The productivity increased 3.5-fold as compared to the original fed-
batch process after normalization to cell culture duration. The major PQAs from this perfusion process were 
consistent throughout the harvest period. Most of the PQAs from the perfusion process showed no significant 
differences from the original fed-batch process. However, significantly higher galactosylation level was observed 
in the perfusion process as compared to its fed-batch version.  In the presentation, we will also detail the 
perfusion medium and process parameter optimization, which enabled the matching of the galactosylation 
profile of the last version perfusion process to the established fed-batch process without compromising target 
VCD, productivities, and other PQA profiles. 
 
